Drug Trial Radar · NCT04691661
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Sep 9, 2021
Primary completion
Sep 2, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Il-Yang Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease
Conditions
- Parkinson Disease
Interventions
Radotinib HCl 50 mgDrug
Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of safety parameters: Adverse EventsTime frame: 12 months after dose administration
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
CHRU de Lille - Hôpital Roger Salengro
Lille, France
CHU Limoges
Limoges, France
CHU de Lyon HCL
Lyon, France
Hôpital Nantes-Hotel Dieu
Nantes, France
Hôpital Pitié-Salpêtrière
Paris, France
Chu La Miletrie
Poitiers, France
CHU de Rouen
Rouen, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.